(p.s. REGN)—If AAVL can show that there’s no safety problem with the GT platform per se, AAVL’s GT programs partnered with REGN should be unimpaired. However, to do this, AAVL will have to explain (or fix) what caused the bad OCT retinal-thickness data in the phase-2a AMD trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”